Valerie Diele-Braun nominated to succeed Piet van der Slikke as CEO of IMCD as of January 2024
ROTTERDAM, The Netherlands (15 March 2023) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, is pleased to announce that its Supervisory Board nominates Valerie Diele-Braun to become Chief Executive Officer of IMCD as of January 2024. Valerie will succeed Piet van der Slikke, who in December 2021 announced his intention to retire as CEO in 2024.
Valerie Diele-Braun is currently CEO of CABB Group GmbH, a leading global fine chemicals player and life science company, manufacturing active ingredients as well as advanced intermediates, and has over 20 years of leadership experience in the speciality chemicals and ingredients industry. She has been a member of IMCD’s Supervisory Board as of 30 June 2020.
Janus Smalbraak, chair of IMCD’s Supervisory Board: “Valerie brings a wealth of experience in our sector, leading with an international view and mindset. She has a track record of driving long-term business growth. While managing commercial as well as financial performance, Valerie has a keen eye for the sustainability requirements in the industry. Her nomination is the outcome of a thorough succession process. With Valerie we have found an excellent candidate to ensure the continuation of IMCD’s strong management, driving the business in the future ahead.”
Piet van der Slikke, CEO: “I’m delighted to welcome Valerie to our Management Board. Thanks to her role in the Supervisory Board, we have been able to work together in the last three years, in which she came across as an inspiring colleague with a catching mix of energy, experience and personality. I am looking forward to a smooth hand-over, supporting her to lead IMCD in its ambition for sustainable growth.”
Responsibilities
Valerie Diele-Braun has led the German headquartered CABB Group as CEO since 2018. CABB is a global contract development and manufacturing (CDMO) company, with sites throughout the world and a global client base. Prior she has been a member of the Executive Board of Swiss based chemicals manufacturer Achroma, responsible for two of the three global divisions of the company. She had senior executive positions with DSM Nutritional Products and Quest International (now part of Givaudan). Valerie holds a science degree from the State University of New York.
AGM
The appointment proposal will be put to the shareholders for their approval at the upcoming Annual General Meeting (AGM) to be held on 26 April 2023. Subject to shareholder approval, Valerie Diele-Braun will step down from the Supervisory Board and join the Management Board as of 1 October 2023. She will assume responsibilities as CEO and take over from Piet van der Slikke as of 1 January 2024.
To ensure a smooth leadership transition, Piet van der Slikke will remain available as advisor after the handover until 1 April 2024.
This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation and was issued on 15 March 2023, 07:00 a.m. CET.
Attached, please find the full press release in pdf format.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release
VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi
Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa
Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release
BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe
Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release
First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann